Covance Keeping risk in proportion
Keeping risk in proportion - Chris Simmons of Covance explains the importance of adopting a risk-based approach to clinical trials
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
